Severe Impact of Omeprazole Timing on pH‐Sensitive Dasatinib Absorption: Unveiling Substantial Drug–Drug Interaction
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.6173 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Per Andersson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Xspray Pharma, Solna, Sweden. Hauptthemen laut MEDLINE: Omeprazole, Dasatinib, Proton Pump Inhibitors, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Xspray Pharma.
Abstract (Originalsprache)
The absorption and bioavailability of most tyrosine kinase inhibitors are affected by gastrointestinal pH as they are weak basic lipophilic drugs. Hence, concomitant use of acid reducing agents (ARAs) is frequently restricted. Particularly comedication of crystalline dasatinib (Sprycel) and proton‐pump inhibitors (PPIs) should be avoided. Drug–drug interaction (DDI) studies with PPIs report approximately 40%‐80% bioavailability reduction of dasatinib. Limitations in the design of these studies do not allow for assessing the near maximum DDI as timing of PPI dosing was either not reported or 22 h prior to dasatinib intake. We conducted a DDI study of crystalline dasatinib and omeprazole in healthy, fasted participants, investigating the impact of PPI comedication on dasatinib plasma exposure at a time point when the near maximum DDI effect is expected. Participants were administered omeprazole (day 2‐5) to reach steady state. On day 6, a single dose of crystalline dasatinib was given. Crystalline dasatinib dosing alone on day 1 served as control (single dose). The dosing interval between omeprazole administration and crystalline dasatinib was 10 h (median [range: 9‐10 h]). Dasatinib C max and AUC 0‐24 were reduced by 96% and 89% by omeprazole comedication. C max was 224.6 ± 104.7 ng/mL (mean ± SD) and 8.0 ± 4.5 ng/mL ( P < .0001) and AUC 0‐24 was 797.6 ± 274.5 and 90.6 ± 38.1 h·ng/mL ( P < .0001) without and with omeprazole. T 1/2 was 5.7 ± 1.5 h (mean ± SD) with crystalline dasatinib dosing alone and could not be reliably calculated with comedication. To ensure optimal patient outcome, it is vital to investigate bioavailability of pH‐sensitive drugs at the maximal DDI effect of ARAs to understand the worst‐case influence for efficient clinical management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Xspray Pharma, Solna, Sweden.
- Department of Pharmaceutical Biosciences, Translational Drug Discovery and Development, Uppsala University, Uppsala, Sweden.
ORCID-Profile: Magnus Brisander, Hans Lennernäs
Förderung
- Xspray Pharma
Zitieren
APA
Andersson, P., Brisander, M., Liljebris, C., Jesson, G., & Lennernäs, H. (2025). Severe Impact of Omeprazole Timing on pH‐Sensitive Dasatinib Absorption: Unveiling Substantial Drug–Drug Interaction. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.6173
Vancouver
Andersson P, Brisander M, Liljebris C, Jesson G, Lennernäs H. Severe Impact of Omeprazole Timing on pH‐Sensitive Dasatinib Absorption: Unveiling Substantial Drug–Drug Interaction. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.6173
BibTeX
@article{Andersson2025,
author = {Andersson, Per and Brisander, Magnus and Liljebris, Charlotta and Jesson, Gérald and Lennernäs, Hans},
title = {Severe Impact of Omeprazole Timing on pH‐Sensitive Dasatinib Absorption: Unveiling Substantial Drug–Drug Interaction},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.6173}
}
EUVIMED